AllianceBernstein
KROS icon

AllianceBernstein’s Keros Therapeutics KROS Stock Holding History

AllianceBernstein’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$367K Buy
33,200
+2,340
+8% +$26.1K ﹤0.01% 2895
2026
Q1 		$628K Hold
30,860
– – ﹤0.01% 2528
2025
Q4 		$628K Buy
30,860
+3,050
+11% +$53.5K ﹤0.01% 2543
2025
Q3 		$440K Hold
27,810
– – ﹤0.01% 2743
2025
Q2 		$371K Sell
27,810
-700
-2% -$9.45K ﹤0.01% 2811
2025
Q1 		$291K Sell
28,510
-108,914
-79% -$1.26M ﹤0.01% 2785
2024
Q4 		$2.18M Sell
137,424
-20,781
-13% -$1.08M ﹤0.01% 1914
2024
Q3 		$9.19M Buy
158,205
+7,743
+5% +$382K ﹤0.01% 1227
2024
Q2 		$6.88M Buy
150,462
+58,604
+64% +$3.15M ﹤0.01% 1362
2024
Q1 		$6.08M Buy
91,858
+70,738
+335% +$4.19M ﹤0.01% 1391
2023
Q4 		$840K Hold
21,120
– – ﹤0.01% 2360
2023
Q3 		$673K Hold
21,120
– – ﹤0.01% 2425
2023
Q2 		$849K Buy
21,120
+4,820
+30% +$211K ﹤0.01% 2359
2023
Q1 		$696K Hold
16,300
– – ﹤0.01% 2401
2022
Q4 		$783K Buy
16,300
+1,400
+9% +$65.4K ﹤0.01% 2401
2022
Q3 		$561K Sell
14,900
-100
-0.7% -$3.47K ﹤0.01% 2593
2022
Q2 		$414K Buy
15,000
+2,800
+23% +$123K ﹤0.01% 2759
2022
Q1 		$663K Hold
12,200
– – ﹤0.01% 2565
2021
Q4 		$714K Sell
12,200
-2,900
-19% -$145K ﹤0.01% 2594
2021
Q3 		$597K Hold
15,100
– – ﹤0.01% 2692
2021
Q2 		$641K Buy
15,100
+1,500
+11% +$81.3K ﹤0.01% 2709
2021
Q1 		$837K Sell
13,600
-900
-6% -$57K ﹤0.01% 2477
2020
Q4 		$1.02M Buy
14,500
+7,500
+107% +$473K ﹤0.01% 2280
2020
Q3 		$270K Buy
7,000
+900
+15% +$35.7K ﹤0.01% 2857
2020
Q2 		$229K Buy
+6,100
New +$188K ﹤0.01% 2968

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

AllianceBernstein's KROS Position: Q2 2026 in Review

AllianceBernstein increased its Keros Therapeutics (KROS) stake by 7.6% in Q2 2026, buying an estimated $26.1K and bringing the position to 33,200 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #2895.

AllianceBernstein first reported a position in KROS in Q2 2020 and has held it in 25 quarters since. The position peaked at $9.19M in Q3 2024. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • AllianceBernstein held 33,200 shares of Keros Therapeutics worth $367K as of Q2 2026.
  • AllianceBernstein bought 2,340 Keros Therapeutics shares in Q2 2026, an estimated $26.1K.
  • Keros Therapeutics made up ﹤0.01% of AllianceBernstein's portfolio in Q2 2026, its #2895 holding.
  • AllianceBernstein first reported a position in Keros Therapeutics in Q2 2020 and has held it in 25 quarters since.
  • AllianceBernstein's Keros Therapeutics position peaked at $9.19M in Q3 2024.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on AllianceBernstein's 13F filing for Q2 2026, filed 14 Aug 2026.